Correspondence 0001213900-24-113355 from Nok Therapeutics, Inc. (CIK 0002038166)
Nok Therapeutics, Inc. (CIK 0002038166)
Date: Dec. 30, 2024 · CIK: 0002038166 · Accession: 0001213900-24-113355
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 024-12511
Letter
United States Securities and Exchange Commission Office of Life Sciences Re: NÖK Therapeutics, Inc. Offering Statement on Form 1-A Filed September 26, 2024 File No. 024-12511
Dear Mses. Robertson and Dicker and Messrs. Edwards and Campbell,
NÖK Therapeutics, Inc. hereby requests qualification of the above referenced Form 1-A (as amended by Form 1-AA) on or before 12 p.m. on January 3, 2025, or as soon as practical thereafter.
In making this request, the Company acknowledges that:
● Should the Commission or the staff, acting pursuant to delegated authority, qualify the filing, it does not foreclose the Commission from taking any action with respect to the filing;
● The action of the Commission or the staff, acting pursuant to delegated authority, in qualifying the filing, does not relieve the Company from its full responsibility from the adequacy and accuracy of the disclosure in the filing; and
● The Company may not assert staff comments and/or qualification as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States.
Respectfully Submitted,
/s/ Robert Lewis
Show Raw Text
CORRESP
1
filename1.htm
NÖK THERAPEUTICS, INC.
1452 N. US HWY 1, Suite 123
Ormond Beach, FL 32174
December 30, 2024
Vanessa Robertson
Lynn Dicker
Chris Edwards
Alan Campbell
United States Securities and Exchange Commission
Office of Life Sciences
Washington, DC
Re:
NÖK Therapeutics, Inc.
Offering Statement on Form 1-A
Filed September 26, 2024
File No. 024-12511
Dear Mses. Robertson and Dicker and Messrs. Edwards
and Campbell,
NÖK Therapeutics, Inc.
hereby requests qualification of the above referenced Form 1-A (as amended by Form 1-AA) on or before 12 p.m. on January 3, 2025, or as
soon as practical thereafter.
In making this request, the Company acknowledges
that:
●
Should the Commission or the staff, acting pursuant to delegated authority, qualify the filing, it does not foreclose the Commission from taking any action with respect to the filing;
●
The action of the Commission or the staff, acting pursuant to delegated authority, in qualifying the filing, does not relieve the Company from its full responsibility from the adequacy and accuracy of the disclosure in the filing; and
●
The Company may not assert staff comments and/or qualification as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States.
Respectfully Submitted,
/s/ Robert Lewis
Robert Lewis, President, Chief Executive
Officer and Director